BC, H., N, P., S, S., S, N., D, R., S, S., . . . D, F. (2025). Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B).
Citación estilo ChicagoBC, Henzi, et al. Safety and Efficacy of Tamoxifen in Non-ambulant Patients With Duchenne Muscular Dystrophy: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial (TAMDMD Group B). 2025.
Cita MLABC, Henzi, et al. Safety and Efficacy of Tamoxifen in Non-ambulant Patients With Duchenne Muscular Dystrophy: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial (TAMDMD Group B). 2025.
Precaución: Estas citas no son 100% exactas.